Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:BFRI NASDAQ:CVKD NASDAQ:FNCH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.29-0.8%$2.93$1.19▼$85.80$3.03M-0.132.65 million shs118,103 shsBFRIBiofrontera$0.96-3.8%$0.98$0.55▼$1.19$12.80M0.83159,746 shs301,263 shsCVKDCadrenal Therapeutics$3.04-8.7%$4.98$3.02▼$14.64$9.55M1.5967,397 shs76,011 shsFNCHFinch Therapeutics Group$7.30$7.72$2.00▼$16.10$11.72M1.185,025 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-4.41%-2.26%-29.35%-73.20%-93.98%BFRIBiofrontera+15.59%+7.53%+25.00%+12.41%+51.75%CVKDCadrenal Therapeutics-10.00%-20.90%-34.06%-55.84%-75.97%FNCHFinch Therapeutics Group0.00%0.00%-7.80%-43.19%-46.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.29-0.8%$2.93$1.19▼$85.80$3.03M-0.132.65 million shs118,103 shsBFRIBiofrontera$0.96-3.8%$0.98$0.55▼$1.19$12.80M0.83159,746 shs301,263 shsCVKDCadrenal Therapeutics$3.04-8.7%$4.98$3.02▼$14.64$9.55M1.5967,397 shs76,011 shsFNCHFinch Therapeutics Group$7.30$7.72$2.00▼$16.10$11.72M1.185,025 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences-4.41%-2.26%-29.35%-73.20%-93.98%BFRIBiofrontera+15.59%+7.53%+25.00%+12.41%+51.75%CVKDCadrenal Therapeutics-10.00%-20.90%-34.06%-55.84%-75.97%FNCHFinch Therapeutics Group0.00%0.00%-7.80%-43.19%-46.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 1.67Reduce$54.004,086.05% UpsideBFRIBiofrontera 2.00HoldN/AN/ACVKDCadrenal Therapeutics 2.00Hold$13.00327.63% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARTL, CVKD, BFRI, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/27/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/ABFRIBiofrontera$41.71M0.30N/AN/A$0.90 per share1.07CVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$12.88M-$32.74N/AN/AN/AN/A-1,600.12%-224.62%8/12/2026 (Estimated)BFRIBiofrontera-$10.54M-$0.97N/A16.03N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)CVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/ALatest ARTL, CVKD, BFRI, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ARTLArtelo Biosciences-$0.78-$4.00-$3.22-$4.00N/AN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/19/2026Q4 2025BFRIBiofrontera$0.29$0.50+$0.21$0.47$16.15 million$17.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A1.791.79BFRIBiofrontera0.781.201.09CVKDCadrenal TherapeuticsN/A2.682.68FNCHFinch Therapeutics GroupN/A3.873.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BFRIBiofrontera10.08%CVKDCadrenal Therapeutics7.92%FNCHFinch Therapeutics Group21.77%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences3.20%BFRIBiofrontera8.10%CVKDCadrenal Therapeutics26.09%FNCHFinch Therapeutics Group44.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences52.33 million2.26 millionNot OptionableBFRIBiofrontera7012.80 million11.77 millionNo DataCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataARTL, CVKD, BFRI, and FNCH HeadlinesRecent News About These CompaniesBoston biotech company files for Chapter 11 amid financial reorganizationMarch 23, 2026 | msn.comWhat Makes Finch Therapeutics (FNCH) a Worthy Investment?December 11, 2025 | msn.comFNCH - Finch Therapeutics Group Inc Price vs Fair Value - MorningstarJuly 4, 2025 | morningstar.comMFNCH Finch Therapeutics Group, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArquitos Capital's Largest Holdings For Q1 2025May 1, 2025 | seekingalpha.comArquitos Capital Management Q4 2024 CommentaryFebruary 5, 2025 | seekingalpha.comFinch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC DeregistrationOctober 23, 2024 | finanznachrichten.deFinch Therapeutics announces Nasdaq delisting, SEC deregistrationOctober 22, 2024 | markets.businessinsider.comFinch Therapeutics Group to Delist from NasdaqOctober 22, 2024 | markets.businessinsider.comFinch Announces Delisting from Nasdaq and SEC DeregistrationOctober 21, 2024 | globenewswire.comFinch Therapeutics Gr (OTC:FNCH) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comFinch wins US jury trial against Ferring over fecal-transplant patentsAugust 10, 2024 | reuters.comIt is likely that Finch Therapeutics Group Inc (FNCH) Stock will grow upMay 25, 2024 | bovnews.comBFinch Therapeutics Group (NASDAQ: FNCH)April 14, 2024 | fool.comJeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) StockMarch 31, 2024 | insidertrades.comFNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023March 25, 2024 | investorplace.comFinch Therapeutics Group Inc (FNCH)March 7, 2024 | investing.comFinch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest ReportFebruary 22, 2024 | benzinga.comFinch Therapeutics Group Inc FNCHNovember 5, 2023 | morningstar.comMAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)August 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTL, CVKD, BFRI, and FNCH Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.29 -0.01 (-0.77%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Biofrontera NASDAQ:BFRI$0.96 -0.04 (-3.80%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.02 (+2.08%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cadrenal Therapeutics NASDAQ:CVKD$3.04 -0.29 (-8.71%) Closing price 04:00 PM EasternExtended Trading$3.10 +0.06 (+2.14%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Finch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 06/15/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
